T. Rowe Price Investment Management
RPTX

T. Rowe Price Investment Management’s Repare Therapeutics RPTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,796,906
Closed -$21.7M – 630
2023
Q3 		$21.7M Sell
1,796,906
-106,300
-6% -$1.1M 0.02% 469
2023
Q2 		$20.1M Sell
1,903,206
-9,145
-0.5% -$94.2K 0.01% 474
2023
Q1 		$18.8M Sell
1,912,351
-5,675
-0.3% -$65.1K 0.01% 479
2022
Q4 		$28.2M Buy
1,918,026
+155,283
+9% +$2.32M 0.02% 420
2022
Q3 		$21.4M Buy
+1,762,743
New +$22.7M 0.02% 444

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Investment Management's RPTX Position: Q4 2023 in Review

T. Rowe Price Investment Management sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 1,796,906 shares — an estimated $21.7M sold.

T. Rowe Price Investment Management first reported a position in RPTX in Q3 2022 and held it in 5 quarters. The position peaked at $28.2M in Q4 2022. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • T. Rowe Price Investment Management reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,796,906 Repare Therapeutics shares in Q4 2023, an estimated $21.7M.
  • T. Rowe Price Investment Management first reported a position in Repare Therapeutics in Q3 2022 and held it in 5 quarters.
  • T. Rowe Price Investment Management's Repare Therapeutics position peaked at $28.2M in Q4 2022.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.